Tempus HRD
Algorithmic laboratory-developed homologous recombination deficiency assessment using cancer-specific DNA or RNA implementations.
- Developer
- Tempus AI
- Intended use
- Other
- Cancer scope
- Solid tumors
- Specimen
- FFPE tumor tissue
- Molecular modality
- Copy number, DNA mutation, RNA expression
- Current version
- Current Tempus HRD algorithmic LDT (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.